Immune Regulation & CIRS. VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide with wide-ranging physiological effects including va...
VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide with wide-ranging physiological effects including vasodilation, smooth muscle relaxation, immune modulation, and neuroprotection. It has gained particular prominence in the treatment of Chronic Inflammatory Response Syndrome (CIRS) and biotoxin illness, largely through the work of Dr. Ritchie Shoemaker.
VIP binds to VPAC1 and VPAC2 receptors expressed throughout the body. In the immune system, it promotes regulatory T-cell function and shifts immune responses from Th1/Th17 toward Th2, reducing inflammatory cytokine production. In the vascular system, it promotes vasodilation and improves blood flow. In the GI tract, it regulates motility, secretion, and mucosal immune function.
Important: The evidence base for VIP varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.
Intranasal VIP may cause nasal congestion, diarrhea, flushing, and transient hypotension due to vasodilatory effects. Some patients report headache. The Shoemaker Protocol emphasizes checking labs (VIP, MSH, MARCoNS) before initiating VIP therapy.
VIP is not classified under the FDA's Category 1/2 system. It is available as a research compound and through some compounding pharmacies with a prescription for off-label use.
These verified suppliers carry VIP with third-party COAs and US-based shipping.